Eczema drug study for Kids' growth pulled before it started
NCT ID NCT07187089
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to see if dupilumab (Dupixent), an approved eczema drug, could improve growth and bone strength in children aged 6 to 12 with severe atopic dermatitis. It planned to enroll children whose eczema was not controlled by topical treatments. However, the study was withdrawn before any participants were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- dupilumab (Dupixent)
- What this could lead to
- If this study had proceeded, it could have shown that dupilumab helps children with severe eczema grow taller and have stronger bones.
- What could go wrong
- The study was withdrawn before any participants enrolled, so no results are available. It is unknown if dupilumab affects growth or bone density in this age group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Expected to start
-
Nov 2025
An estimate. Start dates often move.
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 to 11 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: 1. Children with body weight ≥15 kg and \<60 kg at screening visit 1 2. Diagnosis of AD according to American Academy of Dermatology consensus criteria at time of screening visit 3. Investigator Global Assessment (IGA) score = 4 at screening and baseline visits 4. ≥15% Body Surface Area (BSA) of AD involvement at the screening and baseline visits 5. Worst Itch Scale score ≥4 at screening visit (for prior 24 hours) and baseline visit (weekly average over prior 7 days) 6. Shorter stature defined for the study as ≤30th height-for-age percentile at screening, as defined in the protocol 7. AD not adequately controlled with topical corticosteroid prescription therapies or when those therapies are not advisable, as defined in the protocol Key Exclusion Criteria: 1. Females who have passed menarche at screening 2. Concomitant skin diseases that may confound AD assessments in the opinion of the investigator 3. Has a known medical issue which may contribute to shorter stature (eg, growth hormone deficiency, Celiac disease) 4. Active helminthic infections; suspected or high risk of helminthic infection, unless clinical and (if necessary) laboratory assessments have ruled out active infection before baseline 5. Has a known allergy or hypersensitivity to components of the study intervention 6. Prior use of dupilumab or other biologic treatment for AD, as defined in the protocol 7. Other advanced systemic treatment for AD within 4 weeks or non-steroidal topical treatments within 2 weeks before the baseline visit NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Severe atopic dermatitis (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.